Skip to main content

THSD7A - Our novel & multifunctional cancer biomarker


Kurzfassung

THSD7A has been identified as a relevant target for the identification and treatment of several types of cancer. While this protein has been already stablished as biomarker for membranous nephropathy, this new application opens the door to very interesting possibilities in a large and steady-growing market. THSD7A measurement is relevant to some major tumor entities, as breast, prostate, renal and colorectal carcinomas.


Hintergrund

Medical diagnosis constantly requires novel, cancer-specific biomarkers that allow a successful and timely identification of tumors.

This innovation presents Thrombospondin Type-1 Domain containing 7A protein (THSD7A) as a new relevant tumor antigen. A direct link between specific tumor entities and the expression level of THSD7A has been revealed.

This new biomarker is favorable to increase the prediction value of in-vitrodiagnostic and prognostic detection methods for cancer, leading to an optimized early diagnosis and treatment decision.

Furthermore the innovation offers the possibility to treat THSD7A expressing cancer cells selectively with cytotoxic compounds linked to anti-THSD7A antibodies to optimize site directed drug application and minimize therapeutic side effects.


Bilder & Videos


Lösung

Immunohistochemistry tests performed on more than 70 tumor entities (including 20.000 tissue spots), using tissue microarrays, have demonstrated the association between the THSD7A marker and the described tumor entities.

THSD7A antibodies are measurable in blood, stressing its determination as powerful screening for tumor identification.

Additional tests have shown a strong correlation also with Membranous Nephropathy (MN), a severe renal disorder. THSD7A positive MN is a strong indicator for a synchronously existing malignancy.

Important advantages for tumor screening are associated with THSD7A:

 

  • THSD7A antibodies detectable in serum, plasma or blood
  • Relevant expression in different neoplasias:
    • Breast
    • Prostate
    • Renal
    • Colorectal
    • etc.

Vorteile

Extensive experimental results performed on human tumor tissue support the strong relation between THSD7A and several tumor entities, thus describing a robust and multifunctional biomarker.

This advance opens the door to innovative tools for personalized medicine in cancer treatment, which shall directly improve patient care through early diagnosis of the disease and efficient therapy.


Anwendungsbereiche

  • Cancer Biomarker
  • Cancer Diagnosis & Therapy
  • Membranous Nephropathy
  • Personalized Medicine

Service

  • Development Cooperation
  • Licensing
  • Patent Sale

TUTECH INNOVATION GMBH

Dr. Francisco Blanco
040-766296587
blanco@tutech.de
https://tutech.de/
Adresse
Harburger Schloßstraße 6-12
21079 Hamburg



Entwicklungsstand

Präklinik


Patentsituation

  • PCT PCT/EP2017/057347 anhängig

Stichworte

New cancer biomarker, Breast cancer, Colorectal cancer, Prostate cancer, Renal cancer, Tumor antigen

Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr